Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2026-04-09 Annual Report
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT Therapeutics - Annual Report 2025 - Attachment: 2025 EXACT Therapeutics AS Annual Report.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2025' and contains comprehensive sections including a Letter from the CEO, Board of Directors' Report, Financial Review, and detailed financial statements (Operating expenses, Financial position, Cash flow). It covers the company's activities, strategy, and financial performance for the full fiscal year 2025, fitting the definition of an Annual Report (10-K). FY 2025
2026-04-09 English
EXACT Therapeutics - Annual Report 2025
Report Publication Announcement Classification · 92% confidence The document is a brief notice stating “Please find enclosed the 2025 Annual Report” without containing the report’s financials or detailed management commentary. At under 1,000 characters and serving solely to publish or attach the report, it fits the Report Publication Announcement category rather than the full Annual Report itself.
2026-04-09 English
EXACT Therapeutics AS: Share capital increase registered
Share Issue/Capital Change Classification · 95% confidence The document is a short stock exchange announcement stating that the company’s share capital increase—resulting from the issuance of new shares upon exercise of warrants—has been registered with the Norwegian Register of Business Enterprises. This is clearly an announcement of a capital change (new share issue) rather than a full report or other regulatory filing. Therefore, the correct classification is Share Issue/Capital Change (SHA).
2026-03-26 English
EXACT Therapeutics AS - Minutes from extraordinary general meeting on 13 March 2026 - Attachment: 20260313_EXACT_Therapeutics_-_EGM_minutes.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is the official minutes of an Extraordinary General Meeting (EGM) for EXACT Therapeutics AS. It details the agenda items, voting results, and specific resolutions passed, including a share capital increase. This document serves as the formal record of the meeting's proceedings and the resulting shareholder decisions, which falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2026-03-13 Norwegian
EXACT Therapeutics AS - Minutes from extraordinary general meeting on 13 March 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'Minutes from extraordinary general meeting' and details the adoption of proposals regarding share capital changes following a warrant exercise. While it mentions the minutes are enclosed, the primary purpose of this filing is to report the official results of the shareholder vote at the extraordinary general meeting. Therefore, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2026-03-13 English
EXACT Therapeutics - First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer
Regulatory Filings Classification · 95% confidence The document is a press release announcing a clinical trial milestone (first patient dosed in a Phase 2 trial). It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement. As it is a general corporate announcement regarding clinical progress, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate news.
2026-03-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.